No more complementary vaccinations against measles for children aged six months The measles epidemic, the first case of which occurred in the Netherlands in May 2013, is coming to an end.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Nanotechnology in the fight against cancer Nanotechnology offers improved options for the diagnosis and treatment of cancer.
Human and veterinary health sectors join forces for responsible use of antibiotics. Bacteria that are resistant to almost all antibiotics continue to spread across Europe. This was revealed by new figures from the European Centre for Disease Prevention and Control (ECDC).
In The Spotlight: Young Researchers RIVM 'Young Researchers' present their PhD research in 4 short films which were made especially to highlight and explain their scientific research.
Teenage girl dies after measles infection Last weekend, a 17-year-old girl from the province of Zeeland (The Netherlands) has died of complications after a measles infection. She was not vaccinated against the disease.
Extra measles vaccinations for risk groups Some areas of the Netherlands where families for religious reasons chose not to get their babies vaccinated are now reporting cases of measles, and it is expected that the number of cases will incr
Fewer municipalities with low vaccination coverage In the Netherlands, there are 80 municipalities with a low vaccination coverage for one or more vaccinations. This is a decrease compared to last year when there were still 90 municipalities.
Regulation of nanomaterials needs more than definition alone In a new publication, RIVM indicates scientific challenges in the use of the EU definition for nanomaterial in legislation.
EC-definition of nanomaterial provides proper basis In recent years, an increasing number of applications and products containing or using nanomaterials have become available.